Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Tyrosinekinase-remming om myeloïde hypereosinofiel syndroom te behandelen

Werkzaamheid van remming van tyrosinekinase bij het verminderen van eosinofilie bij patiënten met myeloïde en/of steroïde-refractair hypereosinofiel syndroom

The purpose of this study is to evaluate the efficacy of the tyrosine kinase inhibitors, imatinib mesylate and ruxolitinib in reducing peripheral blood eosinophilia in patients with myeloid and/or steroid-refractory hypereosinophilic syndrome (HES). Patients with HES who meet a set of criteria designed to select patients with the myeloid form of the disease, as well as patients without myeloid disease who are refractory to steroid therapy for HES, will be eligible. Imatinib mesylate will be initiated at a dose of 400 mg daily, the FDA-approved dose for the treatment of chronic myelogenous leukemia (CML), in participants with a known imatinib-sensitive mutation and in participants with myeloid features without a JAK mutation. If patients fail imatinib or are steroid-resistant and do not have myeloid features, ruxolitinib therapy will be initiated at a dose of 15 mg twice daily. Patients who demonstrate a clinical and hematologic response at 1 (imatinib arm) or 3 (ruxolitinib arm) months will be eligible to continue therapy. In patients who demonstrate a complete clinical and hematologic response to imatinib therapy (including those who received imatinib prior to enrollment), imatinib may be discontinued. Patients in complete remission for ≥5 years following imatinib are considered cured and will be taken off protocol. Patients receiving ruxolitinib who demonstrate drug-related toxicity and/or a sustained clinical response to ruxolitinib for >2 years may undergo dose de-escalation.

Studie Overzicht

Gedetailleerde beschrijving

This study will evaluate the safety and effectiveness of imatinib mesylate and ruxolitinib in reducing the number of eosinophils (a type of white blood cell) in patients with hypereosinophilic syndrome (HES). Patients with HES have elevated counts of eosinophils in the blood and body tissues, which can cause damage to these tissues. Although HES can involve any tissues, the heart, nerves, and skin are most often affected. Several drugs, including steroids, interferon, and hydroxyurea can lower eosinophil counts; however, these drugs have drawbacks in that they do not work in all patients with HES, or they may work only temporarily, or patients may develop side effects that require stopping the drugs. At the time of study initiation, imatinib mesylate was a new drug approved to treat gastrointestinal tumors and chronic myelogenous leukemia. Some data suggested that imatinib mesylate might be useful in treating a subgroup of patients with HES. The study was subsequently amended to assess long-term response to imatinib and cure in patients with HES. An additional arm was later added to assess the safety and efficacy of ruxolitinib for the treatment of steroid-refractory HES.

Patients with HES who are two (2) years of age and older may be eligible for the imatinib arm of the study. Patients with HES who are 18 years or older may be eligible for the ruxolitinib arm of the study. Candidates will be screened with a medical history, physical examination, blood tests, electrocardiogram (EKG), echocardiogram (ultrasound examination of the heart), pulmonary (lung) function tests, eye exam and a bone marrow examination to determine if they fall into the subgroup of patients likely to respond to these therapies. For the bone marrow procedure, an area of skin and bone is numbed and a very sharp needle is inserted into the bone to draw out a sample of bone marrow for evaluation under the microscope.

Patients enrolled in the imatinib arm of the study will take imatinib mesylate daily. Patients enrolled on the ruxolitinib arm of the study will take ruxolitinib twice daily. Any other drugs they may be taking for HES, as well as other drugs they are taking that may interact with the study treatment, will be tapered and stopped. If it is not possible to stop taking certain drugs for other conditions, their dosages may be adjusted. Patients will be monitored weekly with laboratory testing during the first month of treatment and whenever neutrophil counts drop below 1500/mm^3 or platelets fall below 100,000/mm^3. If blood counts remain high enough, monitoring will be reduced to every 2 weeks for three (3) months and once a month after that. Patients receiving imatinib will have a clinic visit at NIH one (1) month after beginning the drug for a clinical and laboratory evaluation, including a repeat bone marrow examination. Patients receiving ruxolitinib will have a clinic visit at NIH 1 month after beginning the drug for a clinical and laboratory evaluation, and at 3 months for repeat evaluation, including a repeat bone marrow examination. Patients receiving imatinib whose eosinophil counts are not lowered after 4 weeks of treatment will leave the study. Those who respond to therapy will return to NIH every 3 months for a history and physical examination, laboratory tests, EKG, echocardiogram, and pulmonary function testing to determine how treatment is affecting disease progression. In some participants with stable disease where an optimal dose of imatinib mesylate has been identified, visits may be extended to every six months. Patients who achieve clinical, hematologic and molecular remission for > 2 years may undergo treatment interruption to assess for durable cure. Patients receiving ruxolitinib will undergo clinical assessments at 1 and 3 months, with repeat bone marrow examination after a minimum of 2 months of therapy. Clinical responders will continue on study with assessment every 3 months for at least one year, after which the interval between visits may be extended. In addition to the clinical assessments, the following procedures will be done solely for research purposes:

  • Blood tests to determine the effects of the study drug on immune cells, including eosinophils.
  • Leukapheresis to study the effects of imatinib mesylate on eosinophils: For this procedure, whole blood is collected through a needle in an arm vein, similar to donating blood. The blood circulates through a machine that separates it into its components, and the white cells are removed. The rest of the blood is returned to the body, either through the same needle or through another needle in the other arm.
  • Bone marrow examinations will be done during the screening tests and again 1-3 months after starting treatment, depending on the study drug, to look at newly developing cells in the bone marrow.
  • Genetic testing to determine how the study is able to lower eosinophil counts in patients with HES.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

70

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Maryland
      • Bethesda, Maryland, Verenigde Staten, 20892
        • National Institutes of Health Clinical Center

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

2 jaar en ouder (Kind, Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

  • INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  1. Male or female, at least 2 years of age for imatinib therapy and >=18 years of age for ruxolitinib therapy.

  2. Documented diagnosis of HES: eosinophilia >1,500/mm^3 on two occasions, no secondary etiology for the eosinophilia despite careful clinical evaluation, and evidence of end organ damage (histologic evidence of tissue infiltration by eosinophils and/or objective evidence of clinical pathology in any organ system that is temporally associated with eosinophilia and not clearly attributable to another cause).

  3. All participants must fit one of the following four categories:

    1. Myeloid neoplasm associated with a PDGFRA or PDGFRB rearrangement.

    2. Myeloid neoplasm associated with rearrangement or mutation involving the Janus kinase-signal transducers and activators of transcription (JAK-STAT) pathway.

    3. Presence of >=4 of the following laboratory criteria suggestive of a myeloid disorder:

      • Dysplastic eosinophils on peripheral smear
      • Serum B12 level >= 1000 pg/mL.
      • Serum tryptase level >= 12.
      • Anemia and/or thrombocytopenia.
      • Bone marrow cellularity > 80% with left shift in maturation.
      • Dysplastic (spindle-shaped) mast cells on bone marrow biopsy.
      • Evidence of fibrosis on bone marrow biopsy.
      • Dysplastic megakaryocytes on bone marrow biopsy.
    4. Refractory to or intolerant of steroids without evidence of a myeloid disorder.

  4. Negative serum beta-human chorionic gonadotropin 24 hours prior to drug administration for women of childbearing potential to exclude early pregnancy.

  5. Agrees to practice abstinence or effective contraception during administration of imatinib mesylate or ruxolitinib and for 6 months after discontinuation of the drug. Women of childbearing potential who are using hormonal contraceptives and taking ruxolitinib will also be required to use a barrier method.**

  6. Participation in protocol 94-I-0079 (Activation and function of eosinophils in conditions with blood or tissue eosinophilia).

NOTE: Participants who meet inclusion criteria but are already receiving imatinib, may be enrolled in the dose de-escalation portion of the study at the investigator's discretion. Patients who meet inclusion criteria but are already receiving ruxolitinib may be enrolled at the investigator's discretion if baseline data are available and they have received ruxolitinib at the dose specified in the protocol for less than 2 months (primary endpoint).

**Effective contraception includes the use of hormonal (birth control pills, for example) and/or barrier (condoms and diaphragms, for example) methods by participants and/or their partners to prevent pregnancy in women of childbearing potential. For women of childbearing potential who use hormonal methods as their primary means of contraception and will be receiving treatment with ruxolitinib, barrier methods will also be required due to possible interference of ruxolitinib with hormonal contraceptives.

Although a private physician is not required for inclusion in the study, it is strongly recommended that all participants have a physician outside the NIH for routine medical care and emergencies.

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Pregnant or nursing women.*
  2. D816V KIT-positive systemic mastocytosis
  3. Uncontrolled HIV infection (absolute lymphocyte count <200/mm^3 and/or HIV RNA level >500 copies/ml)
  4. Absolute neutrophil count (ANC) <1000/mm^3 or platelet count <10,000/mm^3 or <50,000/m^3 with clinical evidence of bleeding.
  5. Elevated transaminases (>5 times the upper limit of normal) or elevated bilirubin (>3 times the upper limit of normal).
  6. Any condition that, in the investigator s opinion, places the patient at undue risk by participating in the study.

An individual who meets any of the following criteria will be excluded from participation in the ruxolitinib treatment arm of this study:

  1. Evidence of B-cell clonality by polymerase chain reaction (PCR) or flow cytometry.

  2. Active tuberculosis, or acute or chronic active infection with hepatitis B or C*.

  3. Treatment with fluconazole >200 mg daily.

    • Participants with active tuberculosis will be excluded. The most current Infectious Diseases Society of America guidelines will be followed regarding isoniazid therapy for latent tuberculosis. Participants who refuse recommended prophylactic therapy for tuberculosis will be counseled regarding the risks of reactivation of tuberculosis during ruxolitinib therapy but will not be systematically excluded.
    • Molecular and serologic tests for hepatitis B and serology for hepatitis C will be performed regardless of vaccination history. Participants with evidence of active or chronic infection with hepatitis B or positive hepatitis C serology will be excluded from participation in the ruxolitinib arm of the protocol. Specifically, a positive hepatitis B serology indicative of previous immunization (i.e., hepatitis B anti-surface antibody-positive and hepatitis B anti-core antibody-negative) or a fully resolved acute hepatitis B infection is not an exclusion criterion. Patients with an indolent chronic hepatitis B infection (normal alanine aminotransferase (ALT)), aspartate aminotransferase (AST), and albumin, and no radiographic or biopsy evidence of cirrhosis) will be evaluated by an NIH hepatologist and may be eligible. Patients who choose to remain on study with evidence of prior hepatitis B infection will be counseled regarding the risks of reactivation prior to initiation of ruxolitinib therapy.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Sequentiële toewijzing
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Drug therapy 1a: imatinib mesylate in participants with FIP1L1::PDGFRA or PDGFRB translocations

Children age two years and above and adults with steroid-refractory hypereosinophilic syndrome (HES) and FIP1L1::PDGFRA or translocations involving PDGFRB received imatinib mesylate 400 mg oral daily for three months with option to continue treatment for up to twenty years. Imatinib interruption was attempted after a minimum of two years of sustained hematologic and, if appropriate, molecular response.

Initial dosing regimen is 400 mg oral once daily in adults and 260 mg/m^2/day in children with food and a glass of water

Andere namen:
  • Gleevec
Experimenteel: Drug therapy 1b: imatinib mesylate in participants with myeloid neoplasm

Children age two years and above and adults with steroid-refractory hypereosinophilic syndrome (HES) and features suggestive of a myeloid neoplasm without FIP1L1::PDGFRA or a translocation involving PDGFRB, received imatinib mesylate 400 mg oral daily for three months with option to continue treatment for up to twenty years. Imatinib interruption was attempted after a minimum of two years of sustained hematologic response. If participants failed imatinib, ruxolitinib therapy could be initiated at 15 mg oral twice daily.

Initial dosing regimen is 400 mg oral once daily in adults and 260 mg/m^2/day in children with food and a glass of water

Andere namen:
  • Gleevec

Initially dosing regimen is 15 mg orally twice daily

Andere namen:
  • Jakafi
Experimenteel: Drug therapy 1c: imatinib mesylate in participants with non-myeloid neoplasm

Children age two years and above and adults with steroid-refractory hypereosinophilic syndrome (HES) and no features suggestive of a myeloid neoplasm received imatinib mesylate 400 mg oral daily for three months with option to continue treatment for up to twenty years. Imatinib interruption was attempted after 20 years of sustained hematologic response. If participants failed imatinib, ruxolitinib therapy could be initiated at 15 mg oral twice daily.

Initial dosing regimen is 400 mg oral once daily in adults and 260 mg/m^2/day in children with food and a glass of water

Andere namen:
  • Gleevec

Initially dosing regimen is 15 mg orally twice daily

Andere namen:
  • Jakafi
Experimenteel: Drug therapy 2: Ruxolitinib

Adults with steroid-refractory FIP1L1::PDGFRA-negative, PDGFRB translocation negative, BCR::ABL-negative hypereosinophilic syndrome (HES) without myeloid features, or with a known molecular abnormality involving the Janus kinase-signal transducers and activators of transcription (JAK-STAT) pathway or with imatinib-resistant HES with myeloid features received ruxolitinib 15 mg orally twice daily for up to eight years.

Initial dosing regimen is 400 mg oral once daily in adults and 260 mg/m^2/day in children with food and a glass of water

Andere namen:
  • Gleevec

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Participants With an Absolute Eosinophil Count Levels in the Normal Range (<860/mm^3)
Tijdsspanne: One month (for imatinib) and 3 months (for ruxolitinib)

The efficacy of treatment in reducing eosinophilia was estimated after the initiation of treatment as the percentage of participants who reached an absolute eosinophil count (AEC) levels in the normal range defined AEC <860/mm^3 following initiation of therapy. AEC was measured at the same time of day in each participant at specified times before and after treatment.

One month (for imatinib) and 3 months (for ruxolitinib)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Participants With an Absolute Eosinophil Count (AEC) Levels Below 1500/mm^3
Tijdsspanne: One month (for imatinib) and three months (for ruxolitinib) during initial analysis; 12 months for both imatinib and ruxolitinib

The efficacy of treatment in reducing eosinophilia was estimated after the initiation of treatment as the percentage of participants who achieved an absolute eosinophil count (AEC) levels below 1500/mm^3 following initiation of therapy.

One month (for imatinib) and three months (for ruxolitinib) during initial analysis; 12 months for both imatinib and ruxolitinib

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Amy D Klion, M.D., National Institute of Allergy and Infectious Diseases (NIAID)

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

26 september 2002

Primaire voltooiing (Werkelijk)

16 november 2023

Studie voltooiing (Geschat)

10 maart 2027

Studieregistratiedata

Eerst ingediend

24 augustus 2002

Eerst ingediend dat voldeed aan de QC-criteria

24 augustus 2002

Eerst geplaatst (Geschat)

26 augustus 2002

Updates van studierecords

Laatste update geplaatst (Werkelijk)

12 november 2026

Laatste update ingediend die voldeed aan QC-criteria

20 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH-Funded Clinical Trial Information and the Clinical Trials Registration and Results Information Submission rule. As such, this trial will be registered at ClinicalTrials.gov, and results information from this trial will be submitted to ClinicalTrials.gov. In addition, every attempt will be made to publish results in peer-reviewed journals.

IPD-tijdsbestek voor delen

Data can be requested after publication.

IPD-toegangscriteria voor delen

Data from this study may be requested from other researchers at any time after the completion of the primary endpoint by contacting the PI.

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • SAP
  • ICF

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren